Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration

    NEXT STORY
    Roche renews partnership with Sysmex to deliver haematology testing solutions
    PREV STORY
    FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA

    SAINT-GENIS-POUILLY, France, July 27, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA ...

    author_avatar
    NASDAQ Market News

    First Patients Enrolled in UK’s Early Access to Medicines Scheme for Santhera’s Raxone® in Duchenne Muscular Dystrophy (DMD)

    Liestal, Switzerland, September 11, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces enrollment of first DMD ...

    author_avatar
    NASDAQ Market News

    CytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting

    - Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity ...

    author_avatar
    NASDAQ Market News